[Atypical antipsychotics and CATIE-AD. Is this a turning point?].
The Clinical Antipsychotic Trials of Intervention Effectiveness -Alzheimer Disease (CATIE-AD) is the first 36 weeks effectiveness trial of atypical antipsychotics in patients with Alzheimer's disease presenting with behavioral and psychiatric symptoms of dementia (BPSD). There were no significant differences between atypical antipsychotics and placebo in effectiveness measures which also included a cost-benefit analysis. This article not only reviews this landmark study but also summarizes the complex relationship between antipsychotics and BPSD during the last years.
Bustin
Julián
J
Bart's and Royal London Training Scheme. Especialistaen Psiquiatria. julianbusting@gmail.com
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents